RNA medicines built around disease biology
Orbital Therapeutics is advancing a new generation of RNA medicines designed to reprogram cells in vivo, treating diseases at their source. Using a comprehensive set of RNA tools and technologies, the company creates therapies with precision and flexibility to address the underlying biology of immune-driven diseases. Orbital was acquired by Bristol Myers Squibb in October 2025 for $1.5 billion.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2023
Create a free account to see which investors have funded this company.
Create Free Account
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Klick Health is a healthcare marketing and commercialization agency serving life sciences and pha...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
